Evaluating opioid use after surgery in genitourinary cancer patients
Discharge Medication Use Post-Operatively in GU Cancer Patients
This study looks at how much pain medicine people use after surgery for genitourinary cancers and whether they are happy with their care, while also teaching them how to safely get rid of leftover medicine.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 684 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Charlotte, North Carolina) |
| Trial ID | NCT06795087 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the amount of opioids consumed by patients after discharge following surgeries for genitourinary cancers, including cystectomies, nephrectomies, and prostatectomies. Participants will complete a 30-day survey to evaluate their opioid usage and disposal habits, as well as their satisfaction with surgical care. Additionally, an educational pamphlet on proper opioid disposal will be provided to participants starting in the second year of the study. The goal is to understand post-operative opioid consumption and improve disposal practices.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are scheduled for surgical procedures related to genitourinary cancer and will be prescribed opioids for post-operative pain.
Not a fit: Patients who are not undergoing surgery for genitourinary cancer or those who will not be prescribed opioids post-discharge may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management of post-operative pain and safer disposal practices for opioids, reducing the risk of misuse.
How similar studies have performed: While there have been studies on opioid use post-surgery, this specific approach focusing on genitourinary cancer patients and the impact of disposal education is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information. 2. Age ≥ 18 years at the time of enrollment 3. Scheduled to undergo surgical cystectomy, partial or total nephrectomy or prostatectomy for a cancer diagnosis. 4. Ability to read and understand the English and/or Spanish language. 5. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: * None
Where this trial is running
Charlotte, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Stephen Riggs, MD — Wake Forest University Health Sciences
- Study coordinator: Margarita Dzhanumova
- Email: Margarita.Dzhanumova@advocatehealth.org
- Phone: 704-355-2000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.